Abstract:Diffuse midline gliomas (DMGs) are aggressive childhood brain tumors with the H3K27M mutation in the H3F3A or H3C2 gene. Despite treatment advances, radiotherapy is the only viable option, but 99% of patients die within 1.5-2 years. Therefore, there is an urgent need to identify potential novel therapeutic targets for the treatment of DMGs. Ubiquitin-specific protease 1 (USP1) is a key deubiquitinating enzyme involved in genome integrity, cell cycle regulation, and cell homeostasis. USP1 is overexpressed in various cancers, including gliomas, is linked to poor prognosis. It promotes glioma stem cell (GSC) self-renewal and radio-resistance by regulating ID1 and CHEK1. Our recent findings show that ID1 is crucial for DMG invasion and migration. Inhibiting USP1 suppresses malignant growth, enhances radiation sensitivity, and improves chemotherapy response, highlighting its potential for combined therapies. However, USP1's role in DMGs and its feasibility as a therapeutic target remain poorly understood. In this study, we investigated USP1 in DMGs for the first time. RNA sequencing revealed high USP1 expression in DMG patient samples and cell lines, directly linked to the H3K27M mutation. Correcting this mutation reduced USP1 expression in DMG cell lines. Pharmacologic inhibition of USP1 with the specific inhibitor SJB3-019A significantly reduced DMG cell proliferation, triggered apoptosis, and altered cell cycle profile. SJB3-019A-mediated USP1 inhibition decreases migration and invasion in multiple patient-derived DMG cell lines. Additional in vitro experiments revealed that USP1 inhibition leads to a significant decrease in the expression of ID1 and pAKT, suggesting the ID1/AKT pathway as a potential mechanism underlying the observed effects. H3K27M-mediated activation of USP1 in DMG is a promising therapeutic target, with inhibition by SJB3-019A reducing tumor aggressiveness by inhibiting invasion and migration. We will next assess SJB3-019A's efficacy in vivo using genetically engineered isogenic mouse models (GEMM) with DNp53/PDGFRA/H3.3K27M (PPK) alterations and evaluate USP1 inhibition combined with radiation therapy as a potential radiosensitizer in DMGs.

GINS1 promotes the proliferation and migration of glioma cells through USP15-mediated deubiquitination of TOP2A

Knockdown of NUSAP1 Inhibits Cell Proliferation and Invasion Through Down-Regulation of TOP2A in Human Glioblastoma

GINS2 regulates temozolomide chemosensitivity via the EGR1/ECT2 axis in gliomas

USP39-mediated deubiquitination of Cyclin B1 at Lys242 promotes tumor cell cycle G2/M transition and glioma progression

USP39-mediated Deubiquitination of Cyclin B1 Promotes Tumor Cell Proliferation and Glioma Progression

Deubiquitinase USP9X Deubiquitinates Β-Catenin and Promotes High Grade Glioma Cell Growth

USP10 deubiquitinates RUNX1 and promotes proneural-to-mesenchymal transition in glioblastoma

GINS1 promotes the initiation and progression of bladder cancer by activating the AKT/mTOR/c-Myc signaling pathway

Nuclear GSK3β Promotes Tumorigenesis by Phosphorylating KDM1A and Inducing Its Deubiquitylation by USP22

Stabilization of Pin1 by USP34 promotes Ubc9 isomerization and protein sumoylation in glioma stem cells

Ubiquitin‐specific Peptidase 39 Promotes Human Glioma Cells Migration and Invasion by Facilitating ADAM9 Mrna Maturation

Identification of Ubiquitin-Specific Protease 32 As an Oncogene in Glioblastoma and the Underlying Mechanisms

Overexpression of Ubiquitin Specific Proteases 44 Promotes the Malignancy of Glioma by Stabilizing Tumor-Promoter Securin.

UAP1L1 plays an oncogene-like role in glioma through promoting proliferation and inhibiting apoptosis

USP1 Promotes GC Metastasis Via Stabilizing ID2

SENP1-mediated SUMOylation of SIRT1 affects glioma development through the NF-κB pathway

USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1

Loss of Deubiquitylase USP2 Triggers Development of Glioblastoma Via TGF-β Signaling.

Protein Sumoylation with SUMO1 Promoted by Pin1 in Glioma Stem Cells Augments Glioblastoma Malignancy.

Ubiquitin-specific Protease 22 Acts As an Oncoprotein to Maintain Glioma Malignancy Through Deubiquitinating B Cell-Specific Moloney Murine Leukemia Virus Integration Site 1 for Stabilization.

Cnsc-49. Elucidating Therapeutic Potential Of Usp1 Inhibition In Diffuse Midline Gliomas